Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on Obinutuzumab for Adolescents with Active Lupus Nephritis and Safety in Children Aged 5 to 12

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition called Lupus Nephritis, which is a type of kidney inflammation that occurs in people with lupus, an autoimmune disease. The study is testing a treatment called Obinutuzumab, which is a medication given through an infusion into a vein. The purpose of the study is to evaluate how effective and safe Obinutuzumab is for adolescents with active Class III or IV Lupus Nephritis. Additionally, the study will look at the safety and how the body processes the drug in younger children aged 5 to under 12 years old.

Participants in the study will receive either Obinutuzumab or a placebo. The study will last for about 76 weeks, during which time participants will have regular check-ups and tests to monitor their health and the effects of the treatment. The study aims to see if the treatment can help achieve a complete or partial improvement in kidney function and reduce symptoms of the disease. The study will also track any side effects or changes in health that occur during the treatment period.

In addition to Obinutuzumab, the study involves other medications like Myfenax and CellCept, which contain the active ingredient Mycophenolate Mofetil. These medications are used to suppress the immune system and help manage symptoms of Lupus Nephritis. The study will help determine the best way to use these treatments to improve the health of patients with this condition. Participants will be closely monitored to ensure their safety and to gather important information about how these treatments work in young patients.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes a review of medical history and a renal biopsy if not performed in the last 12 months.

    Eligibility criteria include being aged 12 to under 18, having active Class III or IV lupus nephritis, and a positive test for antinuclear antibodies or antibodies to double-stranded DNA.

  2. Step 2

    Randomization and baseline measurements

    Participants are randomly assigned to receive either obinutuzumab or a placebo. Baseline measurements, including urine protein-to-creatinine ratio and estimated glomerular filtration rate, are recorded.

  3. Step 3

    Treatment phase

    Participants receive obinutuzumab as a 1,000 mg intravenous infusion or a placebo at specified intervals. The treatment phase lasts up to 76 weeks.

    In addition to the study drug, participants may receive mycophenolate mofetil in the form of Myfenax 500 mg tablets or CellCept 1 g/5 ml oral suspension, taken orally as prescribed by the study protocol.

  4. Step 4

    Monitoring and follow-up

    Regular monitoring is conducted to assess the safety and effectiveness of the treatment. This includes blood tests, urine tests, and assessments of kidney function.

    Participants are evaluated for any side effects or adverse events throughout the study period.

  5. Step 5

    Completion and final evaluation

    At the end of the 76-week treatment period, a final evaluation is conducted to determine the overall response to the treatment.

    The primary goal is to assess the proportion of participants achieving a complete renal response, as well as any changes in kidney function and disease activity.

Who can join the trial?

6 criteria

  • Participants must be adolescents aged 12 to less than 18 years old at the time of joining the study, or children aged 5 to less than 12 years old.
  • Participants must have **active Lupus Nephritis (LN)**, specifically Class III or IV, as shown by a kidney biopsy done in the last 12 months or during the screening period. A **biopsy** is a test where a small piece of tissue is taken from the body to look for disease.
  • Participants must have a positive test, either currently or in the past, for **antinuclear antibody (ANA)** or **antibodies to double-stranded DNA (dsDNA)**. These are specific blood tests that help diagnose certain autoimmune diseases.
  • Participants can have Class V disease along with Class III or IV LN, but those with only Class V disease cannot join the study.
  • Participants must have **significant proteinuria**, which means having a high level of protein in the urine. This is measured by a urine protein-to-creatinine ratio (UPCR) greater than 0.5 g/g, based on a first-morning urine sample during screening.
  • In the 12 months before or during the screening, all participants must have received at least one dose of **pulse-range IV methylprednisolone** or an equivalent medication. This is a strong anti-inflammatory drug given through a vein to treat the current episode of active LN.

Who cannot join the trial?

3 criteria

  • Patients who do not have **Lupus Nephritis (LN)**, which is a kidney condition related to lupus, cannot participate.
  • Patients who are not within the age range of 5 to less than 12 years old are excluded.
  • Patients who are not part of the vulnerable population selected for the study cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Obinutuzumab is a medication being studied for its effectiveness and safety in treating lupus nephritis, a kidney condition associated with lupus. It is being tested in adolescent patients with active Class III or IV lupus nephritis. The study also includes an evaluation of its safety and how it behaves in the body in a group of younger pediatric patients aged 5 to under 12 years.

What is already known about the treatment

Obinutuzumab – This medication is administered intravenously, meaning it is given directly into a vein. It is currently being studied in clinical trials for its effectiveness and safety in treating lupus nephritis, particularly in adolescents and children. Obinutuzumab is primarily used for its potential to help manage lupus nephritis, a kidney condition associated with lupus. At the molecular level, it works by targeting and binding to a specific protein on the surface of certain immune cells, leading to their destruction. This medication is classified as a monoclonal antibody, which is a type of drug designed to interact with specific targets in the body.

Investigated diseases

Lupus Nephritis – Lupus Nephritis is a kidney disorder that occurs as a complication of systemic lupus erythematosus (SLE), an autoimmune disease. In this condition, the immune system mistakenly attacks the kidneys, leading to inflammation and potential damage. The disease can cause symptoms such as swelling, high blood pressure, and changes in urine, including blood or protein. Over time, the inflammation can impair kidney function, leading to a decrease in the kidneys' ability to filter waste from the blood. The progression of Lupus Nephritis can vary, with some individuals experiencing mild symptoms and others facing more severe kidney involvement. Regular monitoring and management are essential to prevent further kidney damage.
Trial detailsLast updated 2 Oct 2026
Age0-17PhasePhase IITrial ID2023-505825-15-00Protocol codeWA42985Estimated enrolment40 patientsSponsorF. Hoffmann-La Roche AG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).